Skip to main content
Windlas Biotech Limited logo

Windlas Biotech Limited — Investor Relations & Filings

Ticker · WINDLAS ISIN · INE0H5O01029 LEI · 3358008HGGLMCSC4GP83 BSE.NS Manufacturing
Open in API
Filings indexed 435 across all filing types
Latest filing 2025-09-01 Board/Management Inform…
Country IN India
Listing BSE.NS WINDLAS

About Windlas Biotech Limited

https://www.windlasbiotech.com

Windlas Biotech Limited is a Contract Development and Manufacturing Organization (CDMO) providing integrated services from formulation development to commercial-scale production. The company specializes in manufacturing solid and liquid oral dosage forms, including tablets, capsules, sachets, and liquid orals. Its operations encompass three primary business verticals: CDMO services for domestic and multinational firms, trade generics, and over-the-counter (OTC) brands. Windlas maintains advanced research and development facilities focused on process optimization and complex generic formulations. The product portfolio covers diverse therapeutic areas such as gastrointestinal, cardiovascular, anti-diabetic, and respiratory health. The company emphasizes scalable manufacturing solutions and adherence to global quality standards to support the product lifecycles of its pharmaceutical partners.

Recent filings

Filing Released Lang Actions
General Updates
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the appointment of an Investor Relations Agency. It references Regulation 30 of SEBI LODR, which pertains to disclosure of material events. The content is about informing the exchanges of a management-related change (appointment of an IR agency). The document length is short (1509 characters), and it does not contain financial data, audit information, or detailed reports. It is not an announcement of voting results, dividend, or capital changes. The closest fitting category is Board/Management Information (MANG), as it relates to changes in company management or related appointments.
2025-09-01 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides details of the meeting date, time, and format. There is no financial data, report content, or detailed presentation included. The document is an announcement of an event related to investor relations rather than a financial report or detailed investor presentation. Given the short length (2008 characters) and the nature of the content, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement that does not fit into more specific categories.
2025-09-01 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter from Windlas Biotech Limited addressed to stock exchanges (BSE and NSE) informing them about the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(6), which mandates disclosure of such meetings. The content is an announcement of upcoming investor interactions and does not contain any financial data, report, or detailed presentation. The document length is short (2003 characters) and serves as a notification rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-09-01 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter from Windlas Biotech Limited addressed to stock exchanges (BSE and NSE) informing them about the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(6), which mandates disclosure of such meetings. The document does not contain any financial data, results, or detailed presentations but is an announcement of upcoming investor interactions. The document length is about 2000 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about investor meetings and does not fit into more specific categories like Investor Presentation or Call Transcript, which would contain detailed content of the meetings or calls themselves.
2025-08-28 English
General Updates
Remuneration Information Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding the outcome of a Nomination and Remuneration Committee meeting. It details amendments to a stock option plan ('Windlas Plan 2025'), specifically clarifying the maximum number of stock units that may be granted per employee per grant and in aggregate. The document references regulatory compliance with SEBI regulations and provides detailed disclosures about the plan limits. It is not a full report like an Annual Report or Interim Report, nor is it a simple announcement of a report publication. It is also not a call transcript, earnings release, or legal proceeding update. The content focuses on remuneration policy amendments and disclosures related to stock-based employee benefits, which aligns with Remuneration Information filings. The document is substantive and regulatory in nature, detailing compensation plan amendments approved by the Nomination and Remuneration Committee and shareholders. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2025-08-24 English
General Updates
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding amendments to a specific sub-clause of the company's employee stock option plan ('Windlas Plan 2025'). It references regulatory compliance under SEBI Listing Regulations and SEBI Share Based Employee Benefits Regulations. The content focuses on clarifying limits on stock units granted per employee per grant per year. There are no financial statements, earnings data, or detailed financial analysis present. The document is a regulatory announcement about a governance-related amendment to a stock plan, not a full report or financial filing. It fits best under Regulatory Filings (RNS) as it is a compliance disclosure and amendment announcement under SEBI regulations, not a full governance report or remuneration report. The document length is about 5,000 characters, and it is a direct announcement, not a report publication notice.
2025-08-24 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.